Stellenangebote für Clinical Trial Assistant Jobs in München Landkreis

08.04.24 | Vollzeit | Krailling | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Freising | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Königsbrunn | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Friedberg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Dachau | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Planegg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Unterschleißheim | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Fürstenfeldbruck | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing

08.04.24 | Vollzeit | Friedberg | CatalYm GmbHAnd produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical trials, Visugromab is now poised to advance through mid-stage to late-stage clinical development. As we remain steadfast in our commitment to bringing